Targeting activated lymphocytes with an entirely human immunotoxin analogue: Human pancreatic RNase1-human IL-12 fusion

Cytokine

Volumn 12, Issue 6, 2000, Pages 786-790

  Psarras, Kyriakos ^a   Ueda, Masakazu ^a   Tanabe, Minoru ^a   Kitajima, Masaki ^a   Aiso, Sadakazu ^a   Komatsu, Setsuko ^b   Seno, Masaharu ^c  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF AGROBIOLOGICAL SCIENCES   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

Activated lymphocytes; Adult T cell leukaemia; Allograft rejection; Engineered human proteins; IL 2 receptor targeted therapy

Indexed keywords

HYBRID PROTEIN; IMMUNOTOXIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PANCREATIC RIBONUCLEASE; TACROLIMUS;

ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR AFFINITY; RNA TRANSLATION; T CELL LEUKEMIA; TIME;

ANIMALIA; HTLV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 0033939774     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0619     Document Type: Article

References (15)

1. Goldsmith MA, Greene WC. Interleukine-2 and the interleukine-2 receptor. Thomson A. The Cytokine Handbook. 1994;57-80 Academic Press, New York.
2. Semenzato G, Zambello R, Pizzolo G. Interleukine-2 receptor expression in health and disease. Waxman J, Balkwill F. Interleukine-2. 1992;78-105 Blackwell Scientific Publications, Oxford.
3. Schreiber SL, Crabtree CR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 13:1992;136-142.
4. Bach JF. T-cell-directed Immunointervention. 1993;Blackwell Scientific Publications.
5. Kawano F, Yamaguchi K, Nishimura H, Tsuda H, Takatsuki K. Variation in the clinical courses of adult T-cell leukemia. Cancer. 55:1985;851-856.
6. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, Rook A, Saleh M, Schwartz G. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 33:1997;S34-S36.
7. Thrush GR, Lark LR, Clinchy BC, Vitetta ES. Immunotoxins: an update. Annu Rev Immunol. 14:1996;49-71.
8. Rybak SM, Newton DL, Xue Y. RNase and RNase immunofusions for cancer therapy. Tumor Targeting. 1:1995;141-147.
9. Wu YN, Saxena SK, Ardelt W, Gadina M, Mikulski SM, DeLorenzo C, D'Alessio G, Youle RJ. A study of the intracellular routing of cytotoxic ribonucleases. J Biol Chem. 270:1995;17476-17481.
10. Psarras K, Ueda M, Yamamura T, Ozawa S, Kitajima M, Aiso S, Komatsu S, Seno M. Human pancreatic RNase1-human epidermal growth factor fusion: an entirely human "immunotoxin analog" with cytotoxic properties against squamous cell carcinomas. Protein Eng. 11:1998;1285-1292.
11. Yoshida M. HTLV-1 oncoprotein Tax deregulates transcription of cellular genes through multiple mechanisms. J Cancer Res Clin Oncol. 121:1995;521-528.
12. Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science. 239:1988;617-622.
13. Saxena SK, Gravell M, Wu YN, Mikulski SM, Shogen K, Ardelt W, Youle RJ. Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem. 271:1996;20783-20788.
14. Hofsteenge J. Ribonuclease inhibitor. D'Alessio G, Riordan JF. Ribonucleases. Structures and Functions. 1997;621-658 Academic Press, New York.
15. Futami J, Seno M, Kosaka M, Tada H, Seno S, Yamada H. Recombinant human pancreatic ribonuclease produced in E. coli: Importance of the amino-terminal sequence. Biochem Biophys Res Comm. 216:1995;406-413.